AilseVax is a pre-clinical stage BioPharmaceutical company dedicated to the discovery and development of novel cancer therapeutic immunotherapies. The company has IP and technologies to identify novel cancer antigens using cutting edge genomic and and AI / machine learning in our AltRNAV8 platform and new adjuvants to stimulate the immune response to cancer. Our platforms have the potential to synergise with existing cancer treatments and address multiple oncology indications. AilseVax is seeking investors & partnerships to develop more targets and drive our most advanced drug candidate to the clinic.